These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33909311)

  • 1. Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome.
    Wang HY; Mo R; Guan CD; Wang Y; Zhao YY; Xie LH; Zhang R; Cai ZX; Xu B; Dou KF
    Catheter Cardiovasc Interv; 2022 Jan; 99(1):98-113. PubMed ID: 33909311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.
    Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL
    Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial.
    Kedhi E; Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WA; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van' T Hof AW; Lee SW; Roolvink V; Ligtenberg E; Postma S; Kolkman EJ; Brouwer MA; Dudek D; De Luca G
    Atherosclerosis; 2021 Mar; 321():39-44. PubMed ID: 33639478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk "TWILIGHT-like" Patients With Diabetes Mellitus.
    Wang HY; Cai ZX; Yin D; Song WH; Feng L; Gao RL; Yang YJ; Dou KF
    Front Cardiovasc Med; 2020; 7():586491. PubMed ID: 33330647
    [No Abstract]   [Full Text] [Related]  

  • 6. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
    J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
    Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WAW; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van't Hof AWJ; Lee SWL; Roolvink V; Ligtenberg E; Postma S; Kolkman EJJ; Brouwer MA; Kedhi E; De Luca G
    J Thromb Thrombolysis; 2021 Oct; 52(3):797-807. PubMed ID: 33847862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI.
    Wang HY; Xu B; Song CX; Guan CD; Xie LH; Zhao YY; Cai ZX; Yuan S; Dou KF
    J Interv Cardiol; 2022; 2022():3895205. PubMed ID: 35095347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials.
    Verdoia M; Khedi E; Ceccon C; Suryapranata H; De Luca G
    Int J Cardiol; 2018 Aug; 264():30-38. PubMed ID: 29776573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI.
    Wang HY; Gao RL; Xu B; Yang YJ; Yin D; Wang Y; Dou KF
    Platelets; 2021 May; 32(4):533-541. PubMed ID: 32498587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
    Baber U; Dangas G; Angiolillo DJ; Cohen DJ; Sharma SK; Nicolas J; Briguori C; Cha JY; Collier T; Dudek D; Džavik V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta S; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM; Mehran R
    Eur Heart J; 2020 Oct; 41(37):3533-3545. PubMed ID: 33085967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
    Valgimigli M; Smits PC; Frigoli E; Bongiovanni D; Tijssen J; Hovasse T; Mafragi A; Ruifrok WT; Karageorgiev D; Aminian A; Garducci S; Merkely B; Routledge H; Ando K; Diaz Fernandez JF; Cuisset T; Nesa Malik FT; Halabi M; Belle L; Din J; Beygui F; Abhyankar A; Reczuch K; Pedrazzini G; Heg D; Vranckx P;
    Eur Heart J; 2022 Sep; 43(33):3100-3114. PubMed ID: 35580836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
    Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F
    J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
    Wang HY; Dou KF; Wang Y; Yin D; Xu B; Gao RL
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):663-675. PubMed ID: 32601780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: Insights From a Network Meta-Analysis of Randomized Trials.
    Kuno T; Ueyama H; Takagi H; Fox J; Bangalore S
    Cardiovasc Revasc Med; 2021 Jul; 28():50-56. PubMed ID: 32893157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new-generation drug-eluting stent.
    Vranken NPA; Rasoul S; Luijkx JJP; Pustjens TFS; Postma S; Kolkman EJ; Kedhi E; Rifqi S; Lee MKY; Ebelt H; Merkely B; Verdoia M; Wojakowski W; van 't Hof AAWJ; Suryapranata H; De Luca G
    Diabetes Metab Res Rev; 2022 Jul; 38(5):e3530. PubMed ID: 35395144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.